Showing results (101-110 of 106) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Biochemical Pharmacology|May 31, 2011
Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in ratsChang Z Zhu, Chih-Liang Chin, Nathan R Rustay, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 28, 2007
Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathwaysRobert S Bitner, William H Bunnelle, David J Anderson, et al.The Journal of Pharmacology and Experimental Therapeutics|May 28, 2010
In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107John Malysz, David J Anderson, Jens H Grønlien, et al.Journal of Biomolecular Screening|July 15, 2015
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay ParadigmBernard Fermini, Jules C Hancox, Najah Abi-Gerges, et al.Journal of Medicinal Chemistry|May 28, 2004
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractionsWilliam A Carroll, Robert J Altenbach, Hao Bai, et al.CNS Neuroscience & Therapeutics|May 17, 2008
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing propertiesKarin R Tietje, David J Anderson, R Scott Bitner, et al.Pageof 11